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1. Introduction
Oxygen is a basic need for human life. Maintaining adequate oxygen supply is essential for
proper cellular functions. In normal tissue, the oxygen supply usually matches metabolic
requirements, and even if there is a brief oxygen shortage, the body can overcome it by an
increase in the oxygen extracted from the blood or an increase in local blood flow. In advanced
solid tumors, however, due to uncontrolled cell proliferation, the oxygen consumption rate
often exceeds the oxygen available around the area, resulting in local hypoxia. The diffusion
distance from blood vessels to surrounding tissues is usually no more than 100-200 µm;
therefore, the further into the center of the tumors, the lower the oxygen level gets. As
measured by Eppendorf probe, pO2 in normal tissue is between 17 and 65 mm Hg, while in
wide range of tumors, pO2 can go down to 2 mm or even to zero.
As a result of oxygen deficiency, two things can happen to the suffering cells. Cells can either
stop proliferation and die of apoptosis or necrosis, or fight back by taking adaptive processes
that lead to increased proliferation, migration and tissue reorganization. While the ultimate
fate of the cells varies with tissue type, the severity and duration of hypoxia play critical roles
in choosing the direction. In moderate oxygen decline (~ 2-7 mm Hg), the cells in oxygen
starvation and the cells carrying oxygen (red blood cells) run towards each other. Cancer cells
can move away from their original locations to where oxygen is sufficient, while endothelial
cells in the blood vessels can also take an action to move out to form new vessels to bring
oxygen towards the center of hypoxia. The former process is known as metastasis, and the
latter is angiogenesis. Angiogenesis and metastasis support cancer cells to survive through
hypoxic crisis and allow malignant progression. Under severe hypoxic condition (< 1 mm Hg),
however, cells are prone to die of apoptosis if glycolytic ATP available, otherwise, die of
necrosis.
© 2013 Chai; licensee InTech. This is an open access article distributed under the terms of the Creative
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Hypoxia-induced apoptosis proceeds through the mitochondrial pathway, as the mitochon‐
dria are the primary site of oxygen consumption in a cell. Under normoxic conditions, the
mitochondria consume about 90% of available oxygen in the generation of ATP through
oxidative phosphorylation in order to meet the metabolic needs of the cell [1, 2]. When there
is not sufficient oxygen to support this process, mitochondrial damage occurs, which leads to
apoptotic cell death.
To live or to die for a cell under hypoxia is all regulated through different expression and
activation of transcription factors. A number of transcription factors have been reported to
respond to oxygen deficiency, including AP-1 [3], FOS [4], JUN [4], CREB/ATF [5], DEC1 [6],
EGR1 [7], ETS1 [8], GADD153 [9], GATA2 [10], MASH2 [11], NF-IL-6 [12], NFĸB [13], RTEF-1
[14], SMADs [15], SP1 [16], STAT5 [17], and of course, the most popular ones, HIF [18] and p53
[19].
2. Hypoxia inducible factor
Hypoxia inducible factor (HIF) is the best studied transcription factor in hypoxia. When‐
ever there is a discussion about hypoxia,  HIF is always an inevitable topic.  HIF is com‐
posed of two subunits,  α and β. While HIFβ is constitutively expressed, HIFα functions
more like  an oxygen sensor,  varying in  response to  oxygen level  [20].  HIFα has  an ex‐
tremely short  half-life  under  normoxic  conditions  due to  ubiquitination by von Hippel-
Lindau factor  (VHL).  Hypoxia does not  change HIFα expression per  se  but  stabilizes  it
by inhibiting hydroxylation at  prolines 402 and 564 so that  VHL can no longer bind to
HIFα to cause proteasomal degradation. Instead, it  enables HIFα to bind to HIFβ in the
nucleus, generating a functional heterodimeric transcription factor that is able to activate
genes  that  contain  hypoxia-response  elements  (5’-RCGTG-3’),  such  as  genes  coding  for
glucose  transporters,  vascular  endothelial  growth  factor  (VEGF),  inducible  nitric  oxide
synthase  (iNOS),  and erythropoietin  (EPO)  [21,  22].  In  normal  tissue,  the  expression  of
such genes  is  to  counteract  the  detrimental  impact  of  hypoxia  and to  help cells  to  sur‐
vive through oxygen crisis. In cancer, however, this role of HIF is abused to support tu‐
mor growth and resistance to chemotherapy. Up to date, there are three members in HIF
family. HIF-1α is most ubiquitously expressed, while HIF-2α, which shares 48% identity
and similar  functions  with HIF1α,  is  more restricted to  endothelial  cells  [23].  HIF-3α is
the least characterized but may function as a negative regulator of hypoxia, as its dimer
with the β subunit has no transcriptional activity [24].
The most prominent role of HIF during hypoxia is to support angiogenesis through tran‐
scriptional activation of VEGF. VEGF belongs to a family that contains VEGF-A, VEGF-B,
VEGF-C,  VEGF-D,  VEGF-E  and  placenta-like  growth  factor.  VEGF-A,  the  first  growth
factor  that  was  identified  to  have  special  effects  on  endothelial  cells,  further  splits  into
five  isoforms.  VEGF  is  mainly  produced  by  endothelial  cells,  macrophages,  fibroblasts,
and smooth muscle cells. It promotes endothelial cell migration, proliferation and surviv‐
al  through  its  receptors,  VEGFR-1  (Flt-1)  and/or  VEGFR-2  (Flk-1/KDR),  which  are  pre‐
Research Directions in Tumor Angiogenesis30
dominantly expressed on endothelial cells [25]. In addition, VEGF can also bind to three
other transmembrane proteins: VEGFR-3 (Flt-4), which is expressed mainly on lymphatic
endothelial  cells  and only  responds to  VEGF-C and -D,  Neuropilin-1  and Neuropilin-2,
which work as co-receptors with VEGFR-2 [26]. Hypoxia-induced VEGF up-regulation is
considered to be the major driving force for angiogenesis during tumor progression [27].
Tremendous effort has been made in cancer chemotherapy to inhibit this process and has
achieved some significant results,  but some expectations have not been met.  In addition
to VEGF, HIF also regulates several other angiogenic factors such as placenta-like growth
factor, platelet-derived growth factor, angiopoietin-1 and -2 [28].
3. p53
Like HIF, p53 is expressed at a low level under normal oxygen conditions and degraded
constantly by MDM2 through ubiquitination [29,  30].  Under cellular stress like hypoxia,
however,  ATM/ATR  kinases  become  active  and  phosphorylate  p53  at  its  N  terminus,
which disrupts its  interaction with MDM2 and thus,  p53 becomes stabilized and moves
into the nucleus to activate pro-apoptotic genes [31]. As mentioned above, hypoxia indu‐
ces apoptosis through mitochondrial damage. The mitochondrial integrity is guarded by
Bcl-2 family proteins which include anti-apoptotic members like Bcl-2 and Bcl-XL, and al‐
so pro-apoptotic members, such as Bax and Bak. The balance between these two teams is
critical  to the fate of  a cell.  Bcl-2 is  an integral  membrane protein that targets the outer
mitochondrial  membrane, and it  can form homodimers with each other or heterodimers
with Bax. Bax, on the other hand, can do the same. When Bcl-2 predominates, mitochon‐
dria stay intact and cells are protected. However,  while Bax is in excess,  Bax homodim‐
ers become dominant,  the cells  are susceptible to apoptosis.  Bax expression is  regulated
by  p53;  therefore,  p53  activation  increases  the  ratio  of  Bax  to  Bacl-2  and  reduces  the
chance of Bcl-2 and Bax association. It has been postulated that 50% reduction in the for‐
mation of  Bcl-2/Bax complexes  can drive  the  cells  toward apoptosis  [32].  When Bax in‐
serts  into  the  outer  mitochondrial  membrane,  it  opens  pores  to  allow  the  molecules
sequestered in between outer and inner mitochondrial membrane to leak out into the cy‐
tosol.  One  of  the  released  molecules  is  cytochrome  c,  which  can  bind  to  the  apoptotic
protease activating factor-1 (APAF-1] and promote it to form an apoptosome. The apop‐
tosome then binds caspase-9 and activates it to cleave two other caspases, caspase-3 and
-7.  These  two caspases  orchestrate  apoptosis  through cleavage  of  key  substrates  within
the cell, resulting in cell death.
p53 and HIF1α are an odd couple, one supporting cell death and the other supporting cell
survival. These two transcription factors can interact with each other directly because HIF1α
contains two p53-binding sites within its ODD domain [33]. Unlike HIF, p53 appears to be less
sensitive to oxygen level change. Under moderate hypoxic conditions, HIF1α binds to
HIF1β to activate genes that promote cell survival, while p53 still remains inactive. Some in
vitro studies even showed that in such a situation p53 actually promotes HDM2-mediated
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HIF1α degradation [34]. Under severe oxygen poverty, however, HIF1α becomes dephos‐
phorylated and may choose to help p53 to induce cell death [35].
4. Hypoxia activates SRF
Although many transcription factors have been studied extensively under hypoxia [36], the
reaction of serum response factor (SRF) to oxygen shortage has rarely been discussed.
SRF regulates numerous genes that are involved in cellular responses to mitogenic stimu‐
li  as well  as cellular stress [37-39].  These genes fall  into many diversified categories,  in‐
cluding immediate early genes (FOS,  EGR1, etc.),  cytoskeletal  genes (ACTB, CFL1,  DES,
DSTN,  TTN,  KRT17,  etc.),  muscle-related  genes  (ACTA2,  MYH6,  MYH11,  SM22α,
TNNT1, ATP2A1, etc.),  growth factors (IGF2, FGF10, FGFR3, TGFB1i1, etc.),  extracellular
matrix proteins (CCN1, CTGF, etc.), cell adhesion molecules (ITGA1, ITGA5, ITGB1, etc.),
intercellular junctional molecules (TJP1, CDH5, CDH11, etc.), neuronal receptors (NR4A1,
NR4A2, etc.),  and apoptosis regulators (BCL2).  This list  is  still  growing.  All  these genes
contain a common DNA sequence,  CC(A/T)6GG, so-called CArG box or serum response
element (SRE), which SRF recognizes. Some of these genes contain multiple CArG boxes,
for example, EGR1 has six and CCN1 has five, and even SRF itself has four SRE sequen‐
ces [40],  indicating a tight regulation by SRF. In addition to the hundreds of genes that
SRF directly  regulates,  a  growing number  of  genes  that  do  not  contain  SRE have  been
found to respond to SRF activition [41, 42].
Hypoxia is a form of stress to the cells; therefore, it triggers a response from SRF undoubtedly.
As shown in Figure 1, under hypoxic condition, there is not only an increase in the level of SRF
expression (Figure 1A), but also an increase in SRF phosphorylation (Figure 1A), which
enhances SRF binding activity to SRE (Figure 1B). Moreover, this activation of SRF is inde‐
pendent from either HIF or p53, because neither shut down of HIF with its specific inhibitor
Dimethyl Bisphenol A (DBA) (Figure 1C), nor inhibition of p53 with Pifithrin-α (Figure 1D)
has impact on hypoxia-induced SRF activation.
5. SRF supports hypoxia-induced angiogenesis
Previously, we have shown that SRF is required for VEGF-induced in vitro angiogenesis, and
without SRF, VEGF cannot induce endothelial cell proliferation and migration, which are
essential for angiogenesis [43]. Our findings were confirmed and extended later by an in vivo
study on mouse embryonic development, which demonstrated that knockout of SRF in
endothelial cells impairs sprouting angiogenesis from arteries to veins [44]. Transcriptional
analysis showed that SRF deficiency not only had negative impact on genes responsible for
endothelial connection (e.g. VE-cadherin) and adhesion (e.g. integrin α5 and β1), but also
suppressed angiogenic factors like VEGF and angiopoietin-1 and -2.
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Figure 1. Hypoxia activates SRF in mouse brain endothelial cells (bEND3) regardless HIF and p53 status. A. Cells were
cultured in a hypoxic chamber (5% CO2 : 94% N2 : 1% O2) at 37˚C for 2, 6 and 24 hours. Total protein was isolated and
immune-precipitated with an antibody against SRF. Total and phosphorylated SRF were detected by Western blot
analysis. B. SRF protein activity was analyzed by electrophoretic mobility shift assay with P32-labeled consensus SRE
(SRE) and mutant SRE (mSRE) oligos. SRF to SRE binding activity was increased by hypoxic treatment. The lack of bind‐
ing ability to the mutant SRE probe as well as the super shift with the SRF antibody (anti-SRF) confirmed the binding
specificity. C. In the presence of Dimethyl Bisphenol A (DBA), a specific inhibitor for HIF, hypoxic treatment failed to
stabilize HIF1α, but did not affect SRF activation. D. Incubation with p53 inhibitor Pifithrin-α suppressed p53 activation
by hypoxia but did not affect SRF either.
Here we show that hypoxia-induced angiogenic activity in brain endothelial cells is completely
lost when SRF is knocked down by RNA interference (Figure 2), indicating that SRF is essential
to hypoxia-induced angiogenesis. On the other hand, when extra copies of SRF gene are
introduced into these cells, hypoxia-induced angiogenic activity is enhanced. It has been
postulated that hypoxia induces angiogenesis through HIF-VEGF-MAPK/Rho-SRF pathway
[45]. From our previous study [43], we know that VEGF does activate SRF through MAPK and
Rho pathways. However, this is just one side of a coin. As shown above (Figure 1), the increase
of VEGF signaling during hypoxia is due to HIF activation, while hypoxia activates SRF
independently from HIF and therefore, independently from VEGF as well. SRF responds to
hypoxia directly as other transcription factors like HIF and p53. In addition, SRF also serves
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as a downstream regulator in cell proliferation, adhesion and migration, thus any mitogenic
factor that aims to stimulate such cellular activities requires SRF involvement.
Figure 2. Knockdown of SRF in brain endothelial cells (bEND3) prevents hypoxia-induced angiogenesis. bEND3 cells
were cultured in collagen gel matrix under a hypoxic condition. The collagen gel matrix was made of 50% type I colla‐
gen in HEPES (pH 8.5) Hanks buffer balanced growth medium. The mixture was solidified in 12-well plates at 37˚C for
20 minutes. Cells were mixed in the liquid gel, plated on top of the solidified gel in the 12-well plates and incubated at
37˚C for additional 20 minutes. More layers of cells were plated in the wells by repeating this step. Eventually, growth
medium was added to the top of the solidified gel containing endothelial cells and the plates were incubated at 37˚C
for a week. The control cells formed a cobblestone monolayer at the end, while SRF over-expressing cells (SRF+)
moved vertically and horizontally within the gel matrix. The cells with SRF knockdown (SRF-), on the other hand,
stayed inactively. Under hypoxia, both control and SRF+ cells formed cable-like structure, an indication of angiogenic
activity, while the SRF- cells showed sign of death.
6. SRF protects endothelial cells against hypoxia-induced apoptosis
Several studies indicate that hypoxia-induced apoptosis is solely dependent on the mitochon‐
drial pathway [46-48], which is regulated by Bcl-2 family members [49, 50]. Hypoxia induces
an increase in the ratio of the pro-apoptotic protein Bax to the anti-apoptotic protein(s) Bcl-2
and/or Bcl-XL, thereby increases mitochondrial permeability and enables release of cytochrome
c to cytoplasm [51]. Cytochrome c released into the cytoplasm forms complexes with Apaf-1
and triggers a caspase cascade to execute apoptotic cell death [52, 53]. It has been demonstrated
in neuronal cells that hypoxia-induced Bax expression and DNA fragmentation are mediated
through induction of nitric oxide (NO) [54, 55]. NO in endothelial cells is generated by both
the endothelial and inducible isoforms of nitric oxide synthase (eNOS and iNOS) via oxidation
of the substrate, L-arginine. Hypoxia can induce both iNOS and eNOS expression because the
iNOS gene promoter has the hypoxia response element for HIF1 [56, 57] and the eNOS gene
promoter has binding sites for HIF2 [58]. NO has a dual action on the vascular endothelium:
at low concentrations (nM), as are present under basal conditions, it protects cells against
apoptotic stimuli [59]. When its levels become elevated (µM), as in the case of severe ischemia/
hypoxia, NO also initiates apoptosis in both endothelial and non-endothelial cells [60, 61].
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Activation of eNOS, iNOS and SRF is dependent on Rho GTPase-regulated actin dynamics.
Actin de-polymerization activates eNOS [62, 63] and iNOS [64, 65] but suppresses SRF,
resulting in apoptosis [66, 67]. Conversely, actin polymerization activates SRF but suppresses
eNOS and iNOS, supporting cell survival.
Figure 3. Knockdown of SRF in brain endothelial cells increases hypoxia-induced apoptosis. bEND3 cells were cultured
on cover slips under a hypoxic condition for 2, 6 and 24 hours. TUNEL assays were performed to detect apoptosis. Ap‐
parently, overexpression of SRF (SRF+) promoted cell survival, while knockdown of SRF (SRF-) made cells more vulnera‐
ble to hypoxic damage.
Moderate hypoxia induces cell adaptation but not apoptosis. However, when SRF is insuffi‐
cient (SRF-), cells become vulnerable to cellular stress and even a brief oxygen shortage can
trigger apoptotic cell death (Figure 3). On the other hand, forced overexpression of SRF (SRF
+) in these cells can make them more resistant to hypoxic damage and able to survive through
even more harsh oxygen crisis. The advantage of SRF over HIF is its broad involvement in the
molecular regulation of the cell machinery. Once SRF is activated, it not only promotes cell
survival through up-regulation of growth factors and cytoskeletal components, but also
protects mitochondrial integrity through up-regulation of anti-apoptotic proteins like Bcl-2
[68]. In another word, SRF supports cell survival at multiple levels. Up-regulation of growth
factors stimulates cell proliferation and migration, which require adequate supplies of
cytoskeletal proteins, because without cytoskeleton to provide the platform, cells cannot
proliferate or migrate, and SRF makes sure these molecules available at the time of need.
Finally, SRF also makes sure mitochondria intact so that they can provide the energy that cell
proliferation and migration need. Mitochondrial integrity depends on the balance between
pro-apoptotic and anti-apoptotic proteins, typically, BAX versus Bcl-2. Severe hypoxia
activates p53, which drives up-regulation of BAX, pushing cells toward apoptosis, as BAX gene
contains four binding sites for p53. On the other hand, hypoxia also activates SRF (as shown
above), which drives up-regulation of Bcl-2, pushing cells toward survival, as Bcl-2 gene
contains two SREs in its promoter [68]. The BAX and Bcl-2 fight turns into a wrestle between
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p53 and SRF. As shown in Figure 4, manipulation of SRF expression can change BAX/Bcl-2
ratio, and ultimately, change the fate of the cells under hypoxia.
Figure 4. SRF promotes Bcl-2 but suppresses Bax. A. Western blot analysis showed an increase of Bax and a decrease
of Bcl-2 in bEND3 cells due to SRF deficiency. B. Immunocytochemistry showed a similar effect.
The impact of SRF on mitochondrial integrity during hypoxia is not only reflected at the
molecular level, but it can also be visualized at the subcellular level. As shown in Figure 5,
incubation of brain endothelial cells under a hypoxic condition induces mitochondrial leakage,
as reflected by the color change of a fluorescent dye. The longer the hypoxic exposure goes,
the fewer intact mitochondria exist. However, forced overexpression of SRF in these cells can
reverse the effect of hypoxia, protecting mitochondria against hypoxic damage. Conversely,
knockdown of SRF can lower the threshold of mitochondrial tolerance to oxygen deprivation,
so that a short hypoxic exposure can cause a massive mitochondrial leakage.
Research Directions in Tumor Angiogenesis36
Figure 5. Knockdown of SRF in brain endothelial cells increases mitochondrial permeability during hypoxia. bEND3
cells were cultured on cover slips under a hypoxic condition and stained with a cationic dye. The dye fluoresces differ‐
ently in healthy vs. apoptotic cells. In healthy cells, the dye accumulates and aggregates in the mitochondria, giving off
a bright red fluorescence. While in apoptotic cells, the dye cannot aggregate in the mitochondria due to the altered
mitochondrial transmembrane potential, and thus it remains in the cytoplasm in its monomer form, fluorescing green.
Mitochondrial permeability is reflected by the opposite movement of BAX and cytochrome c.
Normally, BAX remains in the cytoplasm at a low level, while cytochrome c hides in between
the inner and outer membranes of the mitochondria. When cells suffer from an oxygen
shortage, BAX jumps, moving toward mitochondria. The insertion of BAX into the outer
mitochondrial membrane opens pores to let cytochrome c leak out. Cytoplasmic cytochrome
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c binds to Apaf-1 and triggers caspase cascade, leading to apoptotic cell death. During this
event, the level of SRF is a determining factor for the fate of the cell. As illustrated in Figure
6, as oxygen crisis prolongs the opposite movement of BAX and cytochrome c increases, and
cells prone to die. Manipulation of SRF level can either facilitate this process or reverse it,
depending on what we desire.
Figure 6. SRF protects mitochondrial integrity. As oxygen deprivation extends, more and Bax binds to mitochondria
and opens up channels to allow cytochrome c to escape from mitochondria into cytoplasm, where it forms complexes
with Apaf-1 and triggers caspase cascade. With overexpression of SRF, cells can reverse Bcl-2/Bax ratio decrease
caused by hypoxia and prevent cytochrome c leakage, while lack of SRF accelerates mitochondrial breakdown.
7. Conclusions
Due to unregulated proliferation of malignant cells, oxygen deficiency is common in tumor
development. Cancer cells have learned a few tricks to survive through oxygen crisis, and one
of them is to stimulate endothelial cells to build new vessels extending oxygen toward the
hypoxic area. However, depending on the severity of hypoxia, endothelial cells may follow
the cue to support tumor growth by engaging in angiogenesis, or commit a suicide by engaging
in apoptosis and leave the tumor cells to die. It is our interest to guide the endothelial cells to
choose the second path. The best known players in the battle against hypoxia are HIF and p53.
In general, HIF up-regulates angiogenic factors to promote angiogenesis, while p53 up-
regulates pro-apoptotic genes to induce apoptosis. However, the relationship between HIF
and p53 is not always a bull-and-bear fight; sometimes they can also join forces to become
friends. HIF can bind to MDM2 to stabilize p53 and thereby to promote apoptosis [69]. It has
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been reported that HIF-deficient embryonic stem cells resist to hypoxia-induced p53 activation
and apoptosis [70]. A similar observation was also reported in neuronal cells where HIF helps
p53 to endorse cell death [71]. For this reason, treatments targeting HIF do not always achieve
inhibition of tumor angiogenesis.
Unlike HIF, SRF promotes cell survival through multi-level and fundamental regulations.
Level 1 – growth factors: as discussed above, SRF is not only activated by growth factors, but
also turns around to stimulate growth factor expression. This positive feedback reinforces the
signal for cell survival. Level 2 – cytoskeletal components: no matter it is for cancer cells to
move away from their primary location to look for new places with better oxygen and nutrient
supply, or for cancer cells to allure endothelial cells with chemicals to form new vessels to
bring oxygen and nutrients to the tumors, cytoskeletal regeneration and rearrangement are
essential requirements. The molecules involved in these processes are tightly controlled by
SRF. As shown in our previous study [43], without SRF, even the most potent angiogenic factor
VEGF cannot stimulate angiogenesis. Level 3 – anti-apoptosis: hypoxia induces apoptosis
through disrupting mitochondrial outer membrane, while mitochondrial integrity is guarded
by Bcl-2, which is controlled by SRF. Therefore, SRF should be a better candidate for cancer
gene therapy, and a treatment targeting SRF, instead of HIF, should achieve better results.
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